Loading...
•
Mar 31, 2021
Artivion Q1 2021 Earnings Report
CryoLife's business returned to growth driven by new product launches, recovery in procedure volume, improved inventory, and international expansion.
Key Takeaways
CryoLife reported a 7% increase in total revenues compared to Q1 2020. The company's growth was driven by new product launches outside the U.S., a recovery in procedure volume in the U.S., an improved JOTEC inventory position, and international expansion efforts.
Total revenues increased by 7% on a GAAP basis.
Net loss was ($3.1) million, or ($0.08) per share.
Non-GAAP net income was $1.4 million, or $0.03 per share.
Company is on-track to file PMAs for PerClot and PROACT Mitral later in 2021.
Forward Guidance
Due to continued uncertainties resulting from the COVID-19 global pandemic, particularly in Europe, the Company is not issuing full year 2021 financial guidance at this time.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...